Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer - Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate

ational Cancer Center Hospital0 sites50 target enrollmentSeptember 9, 2013

Overview

No summary available.

Registry

who.int

Start Date

September 9, 2013

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Female

Sponsor

•a)Patients with brain metastases with symptoms b)Patients with the body cavity fluid marked (pleural effusion, ascites, pericardial effusion). However, it can be registered if good control due to the administration of adhesion agent. c)Patients with synchronous double cancer, not including lesions equivalent to carcinoma in situ or mucosal carcinoma considered healed with topical therapy d)Patients with complications is determined causing serious problems in the implementation of treatment \- Patients with poor control diabetes \- Patients with activity infection \- Patients with pulmonary fibrosis or interstitial pneumonia on chest X\-ray \- Patient with protocol difficult\-to\-treat caused by the mental state or neuropsychiatric disorders \- Patients with watery diarrhea chronic \- Patients with ileus, significant bleeding tendency, and gastrointestinal bleeding \- Patients with uncontrolled angina and myocardial infarction and heart disease merger severe cases with heart failure that developed within three months e)Pregnant or breast\-feeding women, or women of child bearing potential who intend to become pregnant